Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1].
in vivo
Lorvotuzumab mertansine (3-51 mg/kg, i.v., once) has potent anti-tumour activity in CB.17 SCID mice with SW2 SCLC xenograft tumor[1].
Animal Model:
SW2 SCLC xenograft tumor CB.17 SCID mice
Dosage:
3、17 and 51 mg/kg
Administration:
i.v., once
Result:
Showed high anti-tumor activity at a dose of 17 mg/kg with half of the animals being tumor free and complete tumor regression at a dose of 51 mg/kg.
References
[1] Kathleen R Whiteman, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. DOI:10.4161/mabs.27756
